Dashboard
Manage Tickers

VXRT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Dynavax Technologies Collaborates With Vax...
11/05/2025 21:02:58

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing in...

vaxart-withdraws-its-reverse-stock-split-proposal
Vaxart Withdraws Its Reverse Stock Split P...
09/19/2025 12:06:49

Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...

vaxarts-second-generation-oral-norovirus-vaccine-shows-up-to-25-fold-increase-in-protective-fecal-iga-in-phase-1-trial
Vaxart's Second-Generation Oral Norovirus ...
09/10/2025 21:03:32

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against i...

vaxart-q2-eps-007-beats-009-estimate-sales-39730m-beat-2023m-estimate
Vaxart Q2 EPS $(0.07) Beats $(0.09) Estima...
08/13/2025 20:08:16

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19....

vaxarts-earnings-a-preview
Vaxart's Earnings: A Preview
08/12/2025 19:02:15

vaxart-announces-its-common-stock-has-been-approved-to-trade-on-the-otcqx-best-market
Vaxart Announces Its Common Stock Has Been...
07/08/2025 12:10:59

Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/02/2025 12:06:54

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 12:07:35

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
06/13/2025 17:06:07

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/11/2025 12:07:40

vaxart-reports-topline-results-from-phase-1-clinical-trial-evaluating-second-generation-oral-pill-norovirus-vaccine-constructs-head-to-head-against-its-first-generation-constructs
Vaxart Reports Topline Results From Phase ...
06/11/2025 11:32:12

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antib...

Core News & Articles
Why Stitch Fix Shares Are Trading Higher B...
06/11/2025 10:23:30

us-stocks-likely-to-open-lower-ahead-of-may-inflation-report-sp-500-still-in-a-31-month-long-bull-market-better-times-are-coming-says-expert
US Stocks Likely To Open Lower Ahead Of Ma...
06/11/2025 09:56:50

vaxart-board-commits-to-high-end-of-1-for-20-reverse-stock-split-ratio
Vaxart Board Commits To High End Of 1-for-...
05/28/2025 19:11:34

-SEC Filing

vaxart-initiates-dosing-in-10000-participant-portion-of-phase-2b-covid-19-trial
Vaxart Initiates Dosing In 10,000-Particip...
05/27/2025 12:01:15

vaxart-receives-barda-approval-to-initiate-dosing-in-10000-participant-portion-of-ongoing-phase-2b-clinical-trial-evaluating-oral-pill-covid-19-vaccine-candidate
Vaxart Receives BARDA Approval To Initiate...
05/15/2025 12:17:00

Vaxart, Inc. (NASDAQ:VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development ...

vaxart-publishes-complete-data-from-phase-2b-challenge-study-of-first-generation-oral-pill-norovirus-vaccine-candidate-in-science-translational-medicine
Vaxart Publishes Complete Data From Phase ...
05/14/2025 20:17:29

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral sheddingMachine learning a...

vaxart-appoints-jeroen-grasman-as-cfo-effective-may-19-2025-grasman-succeeds-phillip-lee
Vaxart Appoints Jeroen Grasman As CFO, Eff...
05/13/2025 20:06:41

- Mr. Grasman brings over two decades of biotech financial leadership experience -SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GL...

vaxart-q1-eps-007-beats-010-estimate-sales-2088m-beat-955m-estimate
Vaxart Q1 EPS $(0.07) Beats $(0.10) Estima...
05/13/2025 20:06:22

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 ...

Core News & Articles
Earnings Scheduled For May 13, 2025
05/13/2025 08:32:43

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION